CLOVES Syndrome clinical trials at UCSF
1 research study open to eligible people
CLOVES syndrome is a rare condition causing fatty tissue overgrowth and abnormal blood vessels. UCSF is running a Phase 2 study of a targeted drug that blocks PI3Kα in people with PIK3CA gene changes. The study has three parts and measures safety and how overgrowth changes.
Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
open to eligible people ages 2 years and up
This is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, RLY-2608, in adults and children with PIK3CA Related Overgrowth Spectrum (PROS) and malformations driven by PIK3CA mutation. Part 1 is a dose selection, Part 2 is a basket design with exploratory single-arm cohorts for various subpopulations of participants, and Part 3 is randomized, double-blinded study vs placebo.
San Francisco, California and other locations
Last updated: